l e t t e r s Soft-tissue sarcomas, which result in approximately 10,700 diagnoses and 3,800 deaths per year in the United States 1 , show remarkable histologic diversity, with more than 50 recognized subtypes 2 . However, knowledge of their genomic alterations is limited. We describe an integrative analysis of DNA sequence, copy number and mRNA expression in 207 samples encompassing seven major subtypes. Frequently mutated genes included TP53 (17% of pleomorphic liposarcomas), NF1 (10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas) and PIK3CA (18% of myxoid/round-cell liposarcomas, or MRCs). PIK3CA mutations in MRCs were associated with Akt activation and poor clinical outcomes. In myxofibrosarcomas and pleomorphic liposarcomas, we found both point mutations and genomic deletions affecting the tumor suppressor NF1. Finally, we found that short hairpin RNA (shRNA)-based knockdown of several genes amplified in dedifferentiated liposarcoma, including CDK4 and YEATS4, decreased cell proliferation. Our study yields a detailed map of molecular alterations across diverse sarcoma subtypes and suggests potential subtype-specific targets for therapy.
Current understanding of the key genomic aberrations in soft-tissue sarcoma is limited to the most recurrent alterations or translocations. Subtypes with simple, near-diploid karyotypes bear few chromosomal rearrangements but have pathognomonic alterations: translocations in MRCs (t(12;16)(q13;p11), t(12;22)(q13;q12)) and synovial sarcomas (t(X;18)(p11;q11)), and activating mutations in KIT or PDGFRA in gastrointestinal stromal tumors (GISTs) 3, 4 . The discovery of the latter mutations led to the clinical deployment of imatinib for the treatment of GISTs 5 , providing a model for genotype-directed therapies in molecularly defined sarcoma subtypes. In contrast, sarcomas with complex karyotypes, including dedifferentiated and pleomorphic liposarcoma, leiomyosarcoma and myxofibrosarcoma, have no known characteristic mutations or fusion genes, although abnormalities are frequently observed in the Rb, p53 and specific growth-factor signaling pathways 6 .
Recent large-scale analyses 7-10 have established a standard for cancer genome studies, but soft-tissue sarcomas have not yet been a focus of this type of effort. Given the urgent need for new treatments for the ~4,000 people who die each year in the United States of soft-tissue sarcoma 1 , we sought to identify novel genomic alterations that could serve as therapeutic targets. Here we describe complementary genome and functional genetic analyses of seven subtypes of high-grade softtissue sarcoma ( Table 1 and Supplementary Table 1 ) to discover subtype-specific events. Several of our findings, detailed below, could have nearly immediate therapeutic implications.
To study the genomic alterations in sarcomas, we initially analyzed tumor and matched normal DNA from 47 samples encompassing Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy l e t t e r s six soft-tissue sarcoma subtypes. We sequenced 722 protein-coding and microRNA genes, then verified discovered mutations with mass spectrometry-based genotyping (see Online Methods, Supplementary  Fig. 1a and Supplementary Table 2 ). The results revealed 28 somatic nonsynonymous coding point mutations and nine somatic insertions and deletions (indels), involving 21 genes in total ( Table 2 and Supplementary Fig. 1b) . No mutations were detected in microRNA genes. We extended the analysis to an additional 160 tumors, in which we genotyped each of the mutation sites found in the initial sequencing study and resequenced exons of NF1 and ERBB4 in pleomorphic liposarcoma and myxofibrosarcoma, PIK3CA and KIT in MRC and CDH1 in dedifferentiated liposarcoma; this revealed nine additional mutations ( Table 2 and Supplementary Table 3 ).
KIT was frequently mutated in GISTs and, unexpectedly, in one MRC sample (Supplementary Note). The next most frequently mutated genes within specific sarcoma subtypes were PIK3CA in 18% of MRCs, TP53 in 17% of pleomorphic liposarcomas (notably, the only subtype in which mutations of this gene were found), and NF1 in 10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas ( Table 2 and Fig. 1 ). Only one sample of each sarcoma subtype had mutations in any additional genes, including those encoding protein and lipid kinases, as well as known or candidate tumor-suppressor genes (Table 2, Fig. 1 and Supplementary Note) . Further studies will be needed to establish the functional impact of these mutations in sarcoma.
Below, we focus on three specific genomic findings with important therapeutic implications: point mutation or deletion of NF1 in a subset of soft-tissue sarcomas, point mutation of PIK3CA in MRC and a complex pattern of amplification of chromosome 12q in dedifferentiated liposarcoma.
Integrated analysis of DNA copy number, expression and mutation data uncovered diverse alterations of the neurofibromatosis type 1 gene (NF1) in several sarcoma subtypes. Although germline and somatic inactivation of NF1 is associated with malignant peripheral nerve sheath tumors 11 and GISTs in individuals with neurofibromatosis type 1 (ref. 12) , no somatic NF1 alterations have been reported in other sarcomas. We detected 6 point mutations and 12 genomic deletions encompassing the NF1 locus, occurring in both myxofibrosarcoma and pleomorphic liposarcoma ( Table 2 and Figs. 1 and 2; copy number analysis discussed further below). Two of the mutations, nonsense mutations R304* and Q369*), were previously reported as germline mutations in people with neurofibromatosis type 1 (refs. 13,14) , whereas the other four mutations (three missense and one nonsense) have not been previously reported. In some tumors, biallelic inactivation was evident, with heterozygous point mutations accompanied by deletion of the wild-type allele and correspondingly reduced gene expression compared to normal adipose tissue 15 in most cases ( Fig. 2b) . Together, these data indicate a diverse pattern of NF1 aberrations in myxofibrosarcomas and pleomorphic liposarcomas. These results complement recent reports of NF1 alterations in lung cancers and glioblastomas 7, 8 .
PIK3CA, encoding the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), had one of the highest somatic mutation frequencies among the genes in this analysis ( Table 2) . Nucleotide substitutions in PIK3CA were initially detected in 4 of 21 MRCs. We measured the frequency of point mutations in PIK3CA in this subtype by genotyping an independent cohort of 50 MRCs 16 for 13 common sites of PIK3CA mutation, including those discovered in our initial sequencing; mutations were detected in nine additional affected individuals (in total, 13 of 71). The mutations were clustered in two domains, the helical domain (E542K and E545K) and the kinase domain (H1047L and H1047R) ( Table 2) ; both these domains are also mutated in epithelial tumors 17 .
Individuals with MRC whose tumors harbored mutations in PIK3CA had a shorter duration of disease-specific survival than did those with wild-type PIK3CA (P = 0.036, log-rank test). As observed in breast cancers 18 , affected people with helical-domain PIK3CA mutations had worse outcomes than those with kinase-domain mutations ( Fig. 3a) . However, this difference was not statistically significant given the small number of cases in our study.
As both helical-and kinase-domain PIK3CA mutants are believed to activate Akt, although through different mechanisms [19] [20] [21] , we assessed Akt activation in MRC tumors harboring wild-type and mutated PIK3CA. Notably, only E545K helical-domain mutations were associated with increased Akt phosphorylation relative to wild-type, both at Ser473 and Thr308 (TORC2 and PDK1 phosphorylation sites, respectively), and with increased phosphorylation of Akt substrates l e t t e r s PRAS40 and S6 kinase ( Fig. 3b) . To our surprise, tumors with H1047R kinase-domain mutations did not have similar increases in Akt phosphorylation or activation ( Fig. 3b) . However, H1047R-mutant tumors showed variably higher levels of PTEN, a negative regulator of PI3K activity, which may partly explain lower Akt activity. In addition, we detected a single MRC tumor with homozygous PTEN deletion and high Akt phosphorylation levels (data not shown). Further studies are needed to determine the relationship between activated PI3K signaling (resulting from PIK3CA mutations) and the pathognomonic t(12;16)(q13;p11) translocation in this subtype.
In addition to sequencing, we characterized the spectrum of genomic aberrations in soft-tissue sarcoma with 250K SNP arrays for somatic copy number alterations (SCNAs; n = 207; Fig. 1 and Supplementary  Fig. 2a ) and loss of heterozygosity (LOH; n = 200; Supplementary  Fig. 2b) , and with oligonucleotide gene expression arrays (n = 149) (Online Methods). The patterns of statistically significant SCNAs 22,23 ( Fig. 1 ) revealed substantial differences between subtypes with simple and complex karyotypes ( Fig. 1) . MRC, synovial sarcoma and GIST had relatively normal karyotypes compared to dedifferentiated and pleomorphic liposarcoma, leiomyosarcoma and myxofibrosarcoma. In addition, only the four complex subtypes harbored significant copy-neutral LOH (q-value < 0.25; Supplementary Fig. 2b and Supplementary Table 4 ). These types show varied levels of complexity: both dedifferentiated liposarcoma and leiomyosarcoma are less complex than pleomorphic liposarcoma and myxofibrosarcoma ( Fig. 1) . The latter two subtypes had very similar genomic aberrations ( Fig. 1 and Supplementary  Fig. 2a ), indicating they might appropriately be considered a single entity in a molecular classification, as previously suggested 24 .
Our copy number profiling revealed both focal and broad regions of recurrent amplification (Supplementary Table 5 ). The alteration with the highest prevalence in any subtype was chromosome 12q amplification in dedifferentiated liposarcoma (~90%; Figs. 1 and 4a) . As amplification is a common mechanism of oncogenic activation, we designed an RNA interference (RNAi) screen to help identify genes in amplified regions that are necessary for cancer cell proliferation in this subtype. We performed knockdown with shRNAs on 385 genes (Supplementary Table 2 ) in three dedifferentiated liposarcoma cell lines (LPS141, DDLS8817 and FU-DDLS-1) with copy number profiles similar to those observed in primary tumors of this subtype. A total of 2,007 shRNA lentiviruses, a median of five per gene, were tested for their effects on cell proliferation after 5 d (Online Methods).
Using a statistical method, RSA (see Online Methods, Supplementary Note and ref. 25) , we identified 99 genes whose knockdown significantly decreased cell growth in at least one cell line (nominal P < 0.05; Supplementary Table 6 ). For 91 of the 99 genes, two or more independent shRNAs had antiproliferative activity, reducing the likelihood that our results are due to off-target Figure 1 Nucleotide and copy number alterations in soft-tissue sarcoma subtypes. The statistical significance of genomic aberrations for each subtype is shown. RAE q-values (left axis; for visualization, q-values ≤ 0.05 are considered significant, the corresponding false discovery rate being ≤5%) and scores (right axis) for gains and amplifications (red) and losses and deletions (blue) are plotted across the genome (chromosomes indicated at bottom). Genes harboring somatic nucleotide alterations in this study are indicated in each subtype in which they were discovered (table 2). To determine whether the effect of gene knockdown on cell proliferation was specific for dedifferentiated liposarcoma, we compared our results to a pooled shRNA screen of ~9,500 genes in 12 cancer cell lines of different types 26 , which included 58 of the 99 genes whose knockdown reduced proliferation. Only one of the 58 genes, PSMB4, was identified as a common essential gene, for which depletion reduced cell proliferation in ≥8 of 12 cancer cell lines in the prior study 26 .
Of the 99 genes whose knockdown reduced proliferation, 27 were amplified in at least one of the three dedifferentiated liposarcoma cell lines used in our study l e t t e r s ( Supplementary Fig. 3 ). Among these 27 genes, the most strongly overexpressed in dedifferentiated liposarcoma compared to normal fat 15 was CDK4, a cell-cycle regulator and a known oncogene 27 . We confirmed that sustained knockdown of CDK4 (>10 d) inhibited proliferation when we assayed two of the three cell lines we screened (see Online Methods and Fig. 4b ). Furthermore, pharmacological inhibition of CDK4 in dedifferentiated liposarcoma cells with PD0332991, a selective CDK4 and CDK6 inhibitor currently in clinical trials 28 , induced G1 arrest in the same two cell lines ( Fig. 4c) . with tumors that harbor helical-domain mutations (red) compared with kinase-domain mutations (gray) and wild-type PIK3CA (blue). The analysis includes the 65 people for whom outcome information was available. Individuals with MRC who had mutations in either the helical or the kinase domain had shorter disease-specific survival compared to those with wild-type PIK3CA (P = 0.0363, log-rank test). The difference in disease-specific survival between people with helical-domain mutant tumors and those with wild-type PIK3CA tumors was significant (P = 0.013, log-rank test). (b) Protein blots of MRC tumor lysates comparing the levels of phosphorylated Akt, PRAS40 and S6 kinase, as well as their total protein levels, in affected individuals with wild-type PIK3CA or with a mutation in the PIK3CA kinase domain (H1047R) or helical domain (E545K). p-denotes phosphorylation; phosphorylation sites are indicated in parentheses. Genes whose knockdown is antiproliferative in dedifferentiated liposarcoma, and the consequences of CDK4, MDM2 and YEATS4 knockdown in dedifferentiated liposarcoma. VOLUME 42 | NUMBER 8 | AUGUST 2010 Nature GeNetics l e t t e r s For MDM2, another oncogene found in focal 12q amplifications, knockdown did not substantially impair proliferation in our arrayed screen in any of the three cell lines tested. Nevertheless, proliferation was impaired by subsequent knockdown lasting more than a week in two of those three cell lines (Fig. 4d) . Notably, another gene whose knockdown reduced proliferation of cells in which it was amplified was YEATS4 (GAS41), encoding a putative transcription factor that represses the p53 tumor-suppressor network during normal cell proliferation 29 . YEATS4, frequently coamplified with MDM2 (Fig. 4a) , was transcriptionally upregulated both in tumors relative to normal adipose tissue and in tumors with amplification compared to those that were copy neutral for the locus (Supplementary Fig. 3) . Repeat shRNA experiments confirmed the effect of YEATS4 knockdown seen in the arrayed screen ( Fig. 4e) , consistent with the hypothesis that YEATS4 and MDM2 amplification cooperatively repress the p53 network in dedifferentiated liposarcoma, as recently suggested 30 . This finding may have consequences for Nutlin-based antagonism of the p53-MDM2 interaction 15, 31 in dedifferentiated liposarcomas. Our findings lend additional support to the idea that YEATS4 is probably a key amplified gene in cancer, as recently suggested through a weight-of-evidence classification scheme proposed for identifying such amplified cancer genes 32 .
This data set provides the most comprehensive database of sarcoma genome alterations to date, revealing genes and signaling pathways not previously associated with this group of diseases. The study results are available as a community resource that may further the biological understanding of sarcomas and, eventually, shed light on additional strategies to improve patient care. Some of our findings already have potential therapeutic implications. For instance, the PIK3CA mutations found in MRC are, to our knowledge, the first such mutations to be reported in a mesenchymal cancer. These mutations identify a subset of tumors that might respond to treatment with PI3K inhibitors currently in clinical trials 33 . Our results also provide further rationale for use of CDK4 inhibitors in dedifferentiated liposarcoma and suggest the use of mTOR inhibitors in NF1-deficient sarcomas, as loss of NF1 function appears to cause mTOR pathway activation 34 . Finally, these data lend support for the clinical evaluation of agents targeting the p53-MDM2 interaction in dedifferentiated liposarcoma.
This study provides evidence for the therapeutic importance of genomic alterations in sarcoma; the results should encourage pursuit of next-generation sequencing strategies that will continue to define the landscape of genomic aberrations in these deadly diseases. 
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Soft-tissue sarcoma specimens. We procured 207 tumor and 205 matched normal DNA and RNA specimens (blood, fat, or adjacent tissue) at MSKCC from people diagnosed with one of seven high-grade soft-tissue sarcoma subtypes ( Table 1 and Supplementary Table 1 ). Specimens were macro-dissected from two 5-mm hematoxylin and eosin-stained histological sections cut from the top and bottom of a cryomold to assess subtype, percent necrosis, cellularity and stromal contamination. Analyses were conducted from regions with cellularity >75% and no mixed histology, necrosis or fibrosis. This study was conducted with institutional review board approval, and all individuals provided informed consent.
Sequencing. In total, we sequenced 226 protein-coding genes selected on the basis of their validated or hypothesized roles in tumorigenesis, determined from the literature and the CancerGenes resource 35 . These included 90 tyrosine kinase genes, 90 oncogenes and tumor suppressors, 22 sarcoma-related genes, 6 telomere maintenance and stability genes and 18 PI3K-pathway genes not in the former groups (Supplementary Table 2) . We also sequenced 496 microRNAs (87.5% overlap with release 11 of miRBASE) 36 . Samples sequenced (n = 47, Supplementary Table 1 ) had LOH on at least one chromosome arm (according to SNP array analysis), indicating sufficient tumor purity. In total, 3,849 exons and adjacent intronic sequences were PCR-amplified and Sangersequenced. This produced ~27.9 Mb of sequence (~0.58 Mb per sample). We analyzed only amplicons with data for 80% of bases in 80% of the samples, yielding 22.9 Mb (82.1%) and 15 Mb (53.8%) of sequence with 1× and 2× coverage, respectively.
Mutation pipelines and validation. Mutations were initially called using the Broad Institute SNPCompare pipeline, as previously described 37 . Analysis of indels was facilitated by PolyTedh (T. Sharpe and coworkers, unpublished data). The following pipeline, independently developed at MSKCC, was used to supplement mutation detection. Bidirectional reads and sample and gene annotation were consumed from the initial Broad production run. Reads were excluded if their average Phred score was <20 (for bases 100-200) or if they lacked a valid sample, gene, direction or amplicon mapping. Qualified reads were segregated to produce a reference sequence containing coding and UTR exons, as well as 5 kb up-and downstream of the transcription start and stop sites for any transcripts representing the gene. Reads were assembled against the reference using Consed 16.0 (ref. 38) . Assemblies were processed with PolyPhred 6.02b (ref. 39) and SNPdetector version 2 (ref. 40) , and candidate mutation lists were merged without additional filtering. All putative mutations were annotated using the Genomic Mutation Consequence Calculator 41 . Only mutation calls that were supported in both forward and reverse reads, nonsynonymous, indels affecting exonic sequence, or splice site variants (defined as ±4 bp from an exon boundary) were merged with the Broad pipeline output (Supplementary Fig. 1a ). After eliminating intronic candidates (4,355, 77.8%), synonymous mutations (633, 11.3%) and known SNPs (139, 2.5%; dbSNP build 128), 409 and 377 candidate mutations from the two pipelines, respectively, were submitted for mass spectrometric genotyping validation.
To eliminate artifacts, false positives or germline mutations, candidate mutations were independently confirmed in tumor and matched normal samples with mass spectrometry-based genotyping 42 . Of 786 candidate mutations genotyped, 376 (47.8%) were false positives, 296 (37.7%) were germline mutations, 35 (4.5%) resulted from LOH in the tumor, 4 (0.5%) had somatic allele mismatch, 32 (4.1%) failed genotyping, and manual review of traces and spectra eliminated 15 mutations (2%). Therefore, 28 (1.3%) candidate mutations were confirmed somatic. All these were genotyped in the remaining 160 tumor-normal pairs, yielding one additional somatic mutation. We also performed full exon resequencing of several mutated genes in all samples of selected subtypes (Supplementary Fig. 1) . Finally, an independent cohort of 50 MRCs 16 was genotyped for 13 common PIK3CA point mutations (R88Q, N345K, C420R, E542K, E542Q, E545A, E545G, E545D, E545K, M1043I, H1047L, H1047R and H1047Y).
Predicted functional impact of somatic mutations. To predict the likely functional impact of missense mutations, we used the computation method Mutation Assessor (see URLs), which predicts the effect of a given mutated residue on protein function using evolutionary information from protein-family sequence alignments 43 and residue placement in known or homology-deduced three-dimensional protein and complex structures (Supplementary Note). SNP and expression arrays. Genomic DNA was hybridized to the StyI chip (~238,000 SNPs of the 500K Mapping Array Set, Affymetrix), following the manufacturer's instructions. Batches of 96 samples were processed as a plate, with tumor and normal pairs in adjacent wells. Samples and plates were tracked using ABGene 2D barcode tube-rack readers (ABGene). Transcript expression data was obtained for 149 tumors profiled on SNP arrays ( Supplementary  Table 1 ). Cryomold tissue specimens were processed for RNA extraction, and RNA was hybridized on HG-U113A oligonucleotide arrays (Affymetrix) as previously described 15 . Expression of probe sets was estimated with robust multi-array average (RMA) 44 .
Array analysis. Two independent methods, GISTIC 22 and RAE 23 , were used to assess the significance of genome-wide copy number aberrations in each of the seven subtypes. For GISTIC analysis, raw intensity files from SNP arrays were processed and normalized as previously described 22 and as implemented in GenePattern 45 . Separately, RAE was run on the tumors of each subtype as previously described 23 . Known karyotypic complexity determined the false discovery rate (FDR) at which genomic regions were considered significantly altered and regions of interest were determined (for complex and simple karyotypes, FDR ≤ 1% and FDR ≤ 10%, respectively). Segmented copy number data used by either GISTIC or RAE analysis was visualized with the Integrative Genomics Viewer (see URLs). All mapping information was based on Affymetrix annotations and the hg17 build of the human genome sequence.
For RAE analysis, germline CNVs were determined from 173 qualifying normal samples ( Supplementary Table 1 ) after we removed those whose distribution of normalized segmentation (i) was grossly asymmetric (negative or positive skew in diploid peak), (ii) was incoherently multi-modal, (iii) bore isolated copy number genotypes similar to tumors (upon manual review), or (iv) had >2% of the autosomal genome altered. Any segment with A 0 or D 0 ≥ 0.5 was considered altered and presumed polymorphic. These were combined with a subset of known variants (DGV, version 3) 46 . Tumor-specific regions identified by RAE were presumed polymorphic if they appeared in two or more of these sources (or a single matched normal control) and had sequence coverage >50%. Putative polymorphisms were then manually reviewed. Finally, in regions of statistically significant copy number aberration ( Supplementary  Table 5 ), likely aberration states were assigned to isoforms of resident RefSeq genes in each tumor: homozygous deletion (D 1 ≥ 0.9), heterozygous loss (D 0 ≥ 0.9 and D 1 < 0.9), copy-neutral (D 0 and A 0 < 0.9), single-copy gains (A 0 ≥ 0.9 and A 1 < 0.1), and multicopy amplification (A 0 ≥ 0.9 and A 1 ≥ 0.1). We assessed the correlation between transcript expression and copy number with ANOVA; a nominal P < 0.05 was considered correlated.
We generated a consensus copy number profile in dedifferentiated liposarcoma (as in Fig. 4a ) from alterations detected by both GISTIC and RAE using the Fisher method. P values were extracted from either method (representing 193,926 consensus SNPs). Assuming the null hypothesis is true, P values are approximately uniformly distributed, so a statistic k is approximately distributed as a chi-square with 2n degrees of freedom. We let k equal:
where P i is the P value for a SNP from one of the two methods i (n = 2). A combined P value was assigned to each locus, reflecting the consensus significance of both methods. For multiple hypothesis correction (Benjamini and Hochberg FDR), we reduced these to putatively independent observations by calculating the median P value of all SNPs spanning each region of the unified breakpoint profile derived by RAE (therefore correcting 14,814 versus 193,926 tests). The result is a single significance profile of SCNAs in dedifferentiated liposarcoma.
Loss-of-heterozygosity analysis. LOH was determined for 205 tumor-normal sample pairs by the hidden Markov model algorithm in dChipSNP 47 . The genotyping error rate was increased to 0.2; otherwise, default parameters were used. Seven pairs were removed owing to presumptive low data quality (>1,000 LOH segments per sample). For each subtype, GISTIC analysis of LOH was performed as described 22 and overlaid with the GISTIC results for copy loss ( Supplementary Table 4 ).
Cell line analysis. LPS141 and DDLS8817 were derived from high-grade retroperitoneal dedifferentiated liposarcomas 15, 48, 49 , as was FU-DDLS-1 (ref. 50). All were maintained in 1:1 DMEM/F12 medium supplemented with 10% FBS. DNA was extracted with the DNeasy tissue kit (Qiagen), SNP array data was obtained as described for the primary tumors, and data was analyzed with RAE as described above. The amplification status for the 385 genes with shRNA proliferation data was determined in each cell line as loci with A 0 exceeding 0.9 and A 1 exceeding 0.01 (ref. 23 ).
RNA interference screen. In total, 444 genes were identified as significantly amplified in dedifferentiated liposarcoma from a preliminary GISTIC analysis and an early-access version of RAE on a subset (80%) of the final tumor cohort. Of these, 385 genes had one or more shRNAs targeting its transcript in the TRC library 51 and were selected for screening (Supplementary Table 2 ). After optimizing growth conditions, plate types, viral dose and assay times, we plated LPS141 and DDLS8817 in 50 ml at 700 cells per well, and FU-DDLS-1 cells at 900 cells per well, in 384-well plates (Costar 3712) using the MicroFill (BioTek) robot. Medium was replaced after 24 h with 8 μg/ml polybrene using the RapidPlate (Qiagen) or Janus (PerkinElmer) automated pipetting workstations. Cells were then transduced with 1 μl of shRNA lentiviral supernatants using the PerkinElmer Evolution P3 robot. Plates were spun at 1,100g for 30 min and incubated overnight at 37 °C. Infections were performed in quadruplicate, with two replicates placed under puromycin (2 μg/ml) selection 24 h post-transduction. Cell proliferation was measured 5 d post-infection with ATPLite (PerkinElmer). Barcoded plates were read on a PerkinElmer EnVision plate reader. The RNAeye tool (A. Derr, Broad Institute) was used to examine infection efficiency and data quality, to run plate replicate comparisons, to generate hairpin distributions by plate or batch, and to export raw and normalized data by well, hairpin or gene.
Screen analysis and validation. Raw hairpin and well proliferation values were first normalized to Z-scores using the global plate mean and s.d. of proliferation scores 52 . To select hits in each cell line, we used the probabilistic methodology RSA (Supplementary Note). Differential expression of the 385 genes in tumors relative to normal adipose tissue, or between tumors amplified for the gene and those diploid, was determined, respectively, with an empirical Bayes t-test 53 or a two-sample Wilcoxon rank sum test. After multiple hypothesis correction, genes were considered significant at q < 0.05 (FDR < 5%) 54 .
For validation experiments, shGFP-437 and a pLKO.1 virus containing a scrambled 18-bp insert were used as controls, pLKO.1 lentiviruses containing shRNAs targeting CDK4 were from TRC, and those targeting MDM2 and YEATS4, also generated by TRC, were obtained through Open Biosystems. The sequences targeted by the following clones can be found at TRC (see URLs): YEATS4-Y1, TRCN0000013143; YEATS4-Y3, TRCN0000013145; YEATS4-Y4, TRCN0000013146; CDK4-C1, TRCN0000000362; CDK4-C4, TRCN0000000363; CDK4-C8, TRCN0000010520; MDM2-M76, TRCN0000003376; MDM2-M77, TRCN0000003377; MDM2-M78, TRCN0000003380.
For CDK4, cells were trypsinized on day 0 and resuspended at 5 × 10 5 cells per 2 ml medium with 8 μg/ml polybrene (Sigma). We seeded 2 ml into each well of a 24-well plate (Fisher) and added an appropriate titer of lentivirus to achieve ~70% cell infection. A spin infection was performed at 900g for 2 h at 30 °C. Cells were trypsinized and transferred to individual 10-cm dishes. After 24 h, 1.5 μg/ml puromycin was added and infected cells were selected for 72 h, and then 2 × 10 4 cells were seeded per well in six-well plates. Cells were trypsinized and counted using a Vi-Cell XR Cell Viability Analyzer (Beckman Coulter) on days 1, 3, 4, 5 and 11 post-seeding (day 5, 7, 8, 9 and 15 post-infection). For MDM2 and YEATS4, cells were grown to 75% confluence and then infected with lentivirus in six-well plates with polybrene. On day 1, infected cells were selected with 1 μg/μl puromycin. After 72 h, 750 cells were plated per well in 96-well plates (day 4). Plates were collected several days post-seeding, washed with PBS and frozen. Cell quantification was performed using the CyQUANT cell proliferation kit (Invitrogen) on a SpectraMax M2 reader. For protein blotting, lysates were prepared from 10-cm dishes 7 d post-infection. We ran 50 μg of lysate per sample on a Tris-glycine gel. The antibodies used were anti-CDK4 (DCS156, Cell Signaling), anti-MDM2 (sc-965, Sigma), anti-YEATS4 (sc-81278, Sigma) and anti-vinculin (Sigma).
